81
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Is the prognosis of T1-2N1 colon cancer the same as that of T1-2N0 colon cancer after curative surgery?

ORCID Icon & ORCID Icon
Pages 1286-1294 | Received 27 Jan 2023, Accepted 04 Jun 2023, Published online: 22 Jun 2023
 

Abstract

Objectives: The prognoses of T1-2N0 and T1-2N1 colon cancer after curative surgery remain unclear. This study compared the prognoses of patients with T1-2N0 and T1-2N1 colon cancer after curative surgery.

Materials and methods: We retrospectively evaluated 307 consecutive patients with T1-2N0/1 colon cancer who underwent radical surgery at our hospital between January 2010 and December 2016. There were 266 patients with T1-2N0 colon cancer and 41 patients with T1-2N1 colon cancer. After excluding patients with <12 retrieved lymph nodes, 179 patients with T1-2N0 and 32 with T1-2N1 colon cancer were included in the cohort.

Results: Overall survival and disease-free survival did not differ between the T1-2N0 and T1-2N1 groups (p = 0.498 and p = 0.681, respectively). Overall survival and disease-free survival were not significantly different between the T1-2N1 + no chemotherapy and T1-2N1 + chemotherapy groups (p = 0.740 and p = 0.765, respectively). Additionally, overall survival and disease-free survival did not differ between the T1-2N0, T1-2N1 + no chemotherapy, and T1-2N1 + chemotherapy groups (p = 0.757 and p = 0.877, respectively), even after excluding patients with <12 retrieved lymph nodes.

Conclusions: T1-2N1 has a prognosis as good as that of T1-2N0 colon cancer after curative surgery. Moreover, further research is needed to investigate the efficacy of adjuvant FOLFOX chemotherapy in T1-2N1.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The dataset for the current study is available from the corresponding author upon reasonable request.

Additional information

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.